JP2005533013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533013A5 JP2005533013A5 JP2003585713A JP2003585713A JP2005533013A5 JP 2005533013 A5 JP2005533013 A5 JP 2005533013A5 JP 2003585713 A JP2003585713 A JP 2003585713A JP 2003585713 A JP2003585713 A JP 2003585713A JP 2005533013 A5 JP2005533013 A5 JP 2005533013A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- ono
- sno
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940125388 beta agonist Drugs 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 nitroxide free radical Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 239000002840 nitric oxide donor Substances 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 239000002516 radical scavenger Substances 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000004662 dithiols Chemical group 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000524 functional group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 150000002118 epoxides Chemical class 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 claims 1
- LQPOOAJESJYDLS-UHFFFAOYSA-N 1,3-oxazinane Chemical compound C1CNCOC1 LQPOOAJESJYDLS-UHFFFAOYSA-N 0.000 claims 1
- HOQOADCYROWGQA-UHFFFAOYSA-N 1,3-thiazinane Chemical compound C1CNCSC1 HOQOADCYROWGQA-UHFFFAOYSA-N 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 201000004813 Bronchopneumonia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- WITXFYCLPDFRNM-UHFFFAOYSA-N N-Benzylphthalimide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 WITXFYCLPDFRNM-UHFFFAOYSA-N 0.000 claims 1
- 206010030111 Oedema mucosal Diseases 0.000 claims 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000036427 bronchial hyperreactivity Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37417302P | 2002-04-19 | 2002-04-19 | |
| PCT/IL2003/000312 WO2003088961A1 (en) | 2002-04-19 | 2003-04-15 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533013A JP2005533013A (ja) | 2005-11-04 |
| JP2005533013A5 true JP2005533013A5 (enExample) | 2006-06-29 |
Family
ID=29251152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585713A Pending JP2005533013A (ja) | 2002-04-19 | 2003-04-15 | 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7378438B2 (enExample) |
| EP (1) | EP1503754B1 (enExample) |
| JP (1) | JP2005533013A (enExample) |
| AT (1) | ATE310514T1 (enExample) |
| AU (1) | AU2003226603A1 (enExample) |
| DE (1) | DE60302454T2 (enExample) |
| WO (1) | WO2003088961A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE310514T1 (de) | 2002-04-19 | 2005-12-15 | Yissum Res Dev Co | Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen |
| WO2004047837A2 (en) * | 2002-11-22 | 2004-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-blockers having antioxidant and nitric oxide-donor activity |
| JP2006206521A (ja) * | 2005-01-28 | 2006-08-10 | Univ Of Tokyo | 一酸化窒素供与体としてのｎ−ニトロソアミン化合物 |
| TWI645031B (zh) * | 2005-06-24 | 2018-12-21 | 哈尼威爾國際公司 | 含有經氟取代之烯烴之組合物及其用途 |
| GB0708392D0 (en) * | 2007-05-01 | 2007-06-06 | Clearway Medical Ltd | Breathing device |
| WO2011092690A1 (en) | 2010-01-26 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Compositions and methods for prevention and treatment of pulmonary hypertension |
| WO2012037665A1 (en) * | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
| WO2012093383A1 (en) * | 2011-01-04 | 2012-07-12 | Radikal Therapeutics Inc. | Compositions and methods for treatment of sepsis and related conditions |
| CN103018452B (zh) * | 2011-09-20 | 2016-01-13 | 北京勤邦生物技术有限公司 | 一种检测沙丁胺醇药物的胶体金试纸卡及检测方法 |
| WO2014169976A1 (en) * | 2013-04-18 | 2014-10-23 | Nicox Science Ireland | Quinone based nitric oxide donating compounds |
| US10064583B2 (en) | 2013-08-07 | 2018-09-04 | Covidien Lp | Detection of expiratory airflow limitation in ventilated patient |
| HK1223561A1 (zh) | 2013-08-23 | 2017-08-04 | 帕里昂科学公司 | 二巯基化物类粘液溶解剂 |
| MX387071B (es) | 2015-01-30 | 2025-03-19 | Parion Sciences Inc | Agentes mucolíticos de monotiol novedosos |
| US10441568B2 (en) * | 2015-03-26 | 2019-10-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nitroxide radicals for the treatment of diseases of the respiratory tract |
| JP2018520986A (ja) | 2015-04-30 | 2018-08-02 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解剤の新規なプロドラッグ |
| WO2018067838A1 (en) * | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | S-nitrosothiol-mediated hyperbranched polyesters |
| CA3048785A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| WO2018178902A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
| JP2021503029A (ja) | 2017-11-15 | 2021-02-04 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗菌性足場としての一酸化窒素放出性超分岐化合物およびそれに関する方法 |
| AU2019231712B2 (en) | 2018-03-06 | 2025-04-10 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| EP3902841B1 (en) | 2018-12-28 | 2025-01-29 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
| CN112745251B (zh) * | 2019-10-31 | 2023-10-27 | 华创合成制药股份有限公司 | 一种治疗祛痰化合物及其制备方法和用途 |
| WO2022251679A1 (en) * | 2021-05-27 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitroxide radicals for use as antiviral treatment for coronavirus infection |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US6297762B1 (en) | 1979-06-27 | 2001-10-02 | Raytheon Company | Electronic countermeasures system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| WO1990013327A1 (en) | 1989-04-28 | 1990-11-15 | Riker Laboratories, Inc. | Dry powder inhalation device |
| JP3085705B2 (ja) | 1990-01-05 | 2000-09-11 | セプラカー・インコーポレーテツド | 喘息の治療のための光学的純粋ｒ（−）アルブテロール |
| US5364833A (en) | 1990-05-09 | 1994-11-15 | Basf Aktiengesellschaft | Cyclohexenone oxime ethers, their preparation and their use as herbicides |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
| US6060069A (en) | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US5327883A (en) | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
| US5492112A (en) | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| US5821259A (en) | 1991-11-12 | 1998-10-13 | Theoharides; Theoharis C. | H3 -receptor agonists as therapeutic agents |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| US5320094A (en) | 1992-01-10 | 1994-06-14 | The Johns Hopkins University | Method of administering insulin |
| US5277195A (en) | 1992-02-03 | 1994-01-11 | Dura Pharmaceuticals, Inc. | Portable spirometer |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| KR0177265B1 (ko) | 1992-10-19 | 1999-04-01 | 미첼 알. 우드베리 | 건분말 흡입기 |
| US6131567A (en) | 1993-01-29 | 2000-10-17 | Aradigm Corporation | Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
| US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
| US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
| WO1994016756A1 (en) | 1993-01-29 | 1994-08-04 | Miris Medical Corporation | Intrapulmonary delivery of hormones |
| US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| JPH10501519A (ja) | 1994-03-07 | 1998-02-10 | インヘイル・セラピューティック・システムズ | インシュリンを肺に送給できる方法および組成物 |
| WO1995030641A1 (en) | 1994-05-10 | 1995-11-16 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| US5986076A (en) * | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| US5686878A (en) * | 1995-04-03 | 1997-11-11 | Gueli; Carmen | Temperature sensitive fusible link assembly having cooperating projections and slots |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5622166A (en) | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
| AU6031096A (en) | 1995-06-05 | 1996-12-24 | Duke University | Nitrosylated and nitrated superoxide oxidants and reductants |
| US5700904A (en) | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5789442A (en) | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| IT1282686B1 (it) | 1996-02-26 | 1998-03-31 | Nicox Sa | Composti in grado di ridurre la tossicita' da farmaci |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| IL120531A (en) | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
| US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
| AU2662799A (en) | 1998-02-13 | 1999-08-30 | Medinox, Inc. | Modified pharmacologically active agents and improved therapeutic methods employing same |
| IN188837B (enExample) | 1998-05-22 | 2002-11-09 | Torrent Pharmaceuticals Ltd | |
| US6277884B1 (en) | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| AU775388B2 (en) | 1998-11-25 | 2004-07-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Scavenger compounds |
| IL143726A0 (en) | 1998-12-14 | 2002-04-21 | Cellegy Pharma Inc | A pharmaceutical composition containing a nitric oxide donor |
| US20020006901A1 (en) | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| CA2371927A1 (en) | 1999-03-11 | 2000-09-14 | The University Of Manitoba | Nitric oxide manipulation of muscle satellite cell activation |
| GB2349385A (en) | 1999-04-30 | 2000-11-01 | Teijin Ltd | Organic nitrates and nitrites useful against heart disease |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| SE9903985D0 (sv) | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
| US6492405B2 (en) | 1999-12-30 | 2002-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nitric oxide donors and pharmaceutical compositions containing them |
| WO2001051030A1 (en) | 2000-01-10 | 2001-07-19 | Dura Pharmaceuticals, Inc. | Pharmaceutical formulation and method for pulmonary and oral delivery |
| ATE310514T1 (de) | 2002-04-19 | 2005-12-15 | Yissum Res Dev Co | Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen |
-
2003
- 2003-04-15 AT AT03746878T patent/ATE310514T1/de not_active IP Right Cessation
- 2003-04-15 AU AU2003226603A patent/AU2003226603A1/en not_active Abandoned
- 2003-04-15 WO PCT/IL2003/000312 patent/WO2003088961A1/en not_active Ceased
- 2003-04-15 JP JP2003585713A patent/JP2005533013A/ja active Pending
- 2003-04-15 US US10/512,024 patent/US7378438B2/en not_active Expired - Fee Related
- 2003-04-15 DE DE60302454T patent/DE60302454T2/de not_active Expired - Fee Related
- 2003-04-15 EP EP03746878A patent/EP1503754B1/en not_active Expired - Lifetime
-
2008
- 2008-03-10 US US12/045,121 patent/US20080149097A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533013A5 (enExample) | ||
| ES2399179T3 (es) | Tratamiento de enfermedad respiratoria | |
| ES2315425T3 (es) | Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos. | |
| JP2006500394A5 (enExample) | ||
| JP2003515601A5 (enExample) | ||
| CA2465117A1 (en) | Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | |
| JP2002501049A5 (enExample) | ||
| JP2006501181A5 (enExample) | ||
| CA2131797A1 (en) | Condensed indole derivatives as 5ht4-receptor antagonists | |
| JP2005533013A (ja) | 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用 | |
| RU98120057A (ru) | Производные d-пролина | |
| JP2006509749A5 (enExample) | ||
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| JPWO2020123827A5 (enExample) | ||
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| KR960004345A (ko) | 2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 | |
| ES2251180T3 (es) | Composiciones farmaceuticas anti-ulcerosas. | |
| ES2215919T3 (es) | Derivados de cumarina con actividad inhibidora de comt. | |
| ES2784475T3 (es) | Compuestos de 6-hidroxi-2,5,7,8-tetrametilcromano para el tratamiento de enfermedades crónicas obstructivas de las vías respiratorias | |
| JP2005515976A5 (enExample) | ||
| ITMI980442A1 (it) | Sali nitrati di farmaci antiulcera | |
| JP2008534495A5 (enExample) | ||
| WO2006043655A1 (ja) | 吸入用医薬組成物 | |
| JP2009532413A5 (enExample) | ||
| EP1398313A4 (en) | NEW HETEROCYCLIC DERIVATIVES AND THEIR MEDICAL USE |